AMENDMENT NO. 3 TO CONSULTING SERVICES AGREEMENTConsulting Services Agreement • June 28th, 2023 • Vistagen Therapeutics, Inc. • Pharmaceutical preparations
This Amendment (“Amendment No. 3”) is made between Vistagen Therapeutics, Inc., a Nevada corporation having an address at 343 Allerton Avenue, South San Francisco, California 94080 (“Vistagen”), and FitzPatrick & Co. LLC, a Delaware limited liability company, having an address at 2023 Allen Place, NW, Washington DC 20009 (“Consultant”), effective as of July 1, 2023.
CONSULTING AGREEMENTConsulting Agreement • June 28th, 2023 • Vistagen Therapeutics, Inc. • Pharmaceutical preparations
This Consulting Agreement (“Agreement”) is made and entered into as of November 17, 2022, by and between Vistagen Therapeutics, Inc., a Nevada corporation with principal offices located at 343 Allerton Avenue, South San Francisco, CA 94080 (“Vistagen”), and Mark A. Smith, M.D., Ph.D. (“Consultant”). In this Agreement, Vistagen and Consultant are sometimes referred to individually as a “Party” and together as the “Parties.”
AMENDMENT NO. 1 TO MASTER SERVICES AGREEMENT (For All CRO Services)Master Services Agreement • June 28th, 2023 • Vistagen Therapeutics, Inc. • Pharmaceutical preparations
This Amendment (“Amendment No. 1”) is made between VistaGen Therapeutics, Inc., a Nevada corporation having an address at 343 Allerton Avenue, South San Francisco, California 94080 (“VistaGen”) and Allucent (formerly known as Cato Research Ltd.) a North Carolina corporation having an address at 2000 Centregreen Way, Suite 300, Cary, North Carolina 27513 (“Allucent”), and is effective as of June 23, 2022.
